With over 20 years of experience in the pharmaceutical industry, Sophie has held numerous executive roles and has contributed to many commercial successes in oncology, immunology, neuroscience, rare diseases, and endocrinology.

She has led or been involved in more than twenty product launches in France, across Europe, and in emerging markets, during her time at Roche, Sanofi, and Ipsen. This includes major R&D transformation projects at Sanofi and Ipsen, as well as serving as General Manager for the Belgium–Luxembourg region at Ipsen and the biotech company Perha Pharmaceuticals. For the past two years, she has been advising biotech Chief Executive Officers and executive committees on clinical and commercial development of innovative product portfolios, with successful business development outcomes. Sophie holds a degree from ESSEC Business School.

Yves Decadt brings over 25 years of international experience in the pharmaceutical industry. He spent nearly 20 years at Johnson & Johnson within the Global Business Development department, where he was responsible for licensing and deal negotiations, particularly across Asia. He has also held several senior executive positions in leading biopharma and medtech companies. Yves will bring to Poxel a unique combination of scientific and strategic expertise, as well as access to an extensive global network. Since August 2025, Yves has been working with Poxel’s teams under a consultancy agreement, supporting ongoing partnership discussions and conducting an in-depth assessment of the commercial development potential of Poxel’s main assets.

Yves Decadt holds degrees in Bio-Engineering and Industrial Business Administration from University of Ghent (Vlerick School), as well as in Pharmacology and Pharmaceutical Medicine from the Université Libre de Bruxelles. He also holds a Board Director Certification from Duke University.

Amit Kohli has over 3 decades of leadership experience operating at intersection of science, finance and commercialization. Amit has extensive experience in the diabetes therapy area, having held senior roles at Sanofi (1997-2010) and Becton Dickinson (2011-2016) where he launched diabetes-related products across developed and emerging markets growing them to multi-billion euros in revenue.

Lately, as Chief Executive Officer of privately held biotech, Antev (2020 onwards), he led the company’s $75M sale to Medicus (NASDAQ: MDCX).

Mr. Kohli has held Global and regional leadership roles at Pharnext, Eurofins, Becton Dickinson and Sanofi, encompassing sales, marketing, finance, supply chain and manufacturing.

Mr. Kohli earned an M.B.A. in Finance from the Management Development Institute (MDI) Gurgaon, in India and a Bachelor of Mechanical Engineering from the University of Pune in India.

Alexandre Bragadir has been a Senior Investment Director at IPF Partners, a fund specializing in non-dilutive financing for innovative healthcare companies across Europe. He structures and oversees debt investments, having been involved with a dozen companies in the biotech, biopharma, medtech, and digital health sectors over the past six years. He began his career in 2003 in audit at Salustro Reydel before joining BNP Paribas, in strategic client coverage in Portugal, in structured finance in Paris, and in commodity trade finance team in Geneva. Alexandre holds a degree from ESCP Europe.